Related Experiment Video
Updated: Jun 11, 2025
05:35
Ovarian Cancer Patient-Derived Organoid Models for Pre-Clinical Drug Testing
Published on: September 15, 2023
1.4K
In vitro drug testing using patient-derived ovarian cancer organoids
Lin-Yu Chen1, Yu-Ting Chou1, Phui-Ly Liew2,3
1Department of Obstetrics and Gynecology, Shuang Ho Hospital, Taipei Medical University, New Taipei City, 23561, Taiwan.
Journal of Ovarian Research
|October 2, 2024
Summary
Patient-derived organoids (PDOs) show promise for predicting ovarian cancer chemotherapy response. This approach may lead to more personalized cancer treatments and drug development.
Area of Science:
- Oncology
- Biotechnology
- Genomics
Background:
- Ovarian cancer is a leading cause of gynecological cancer mortality.
- Current chemotherapy response rates are limited, especially for advanced or recurrent disease.
- A need exists for strategies to optimize chemotherapy selection.
Purpose of the Study:
- To generate patient-derived organoids (PDOs) from ovarian cancer.
- To assess drug sensitivities of these PDOs in vitro.
- To correlate organoid drug responses with patient clinical outcomes.
Main Methods:
- PDOs were established from surgical tumor specimens.
- Histopathological and molecular characterization confirmed PDO fidelity.
- In vitro drug sensitivity testing was performed using a 3D cell viability assay.
Main Results:
- 31 PDOs were successfully generated, with 28 expandable.
- Organoid drug testing revealed significant inter-patient heterogeneity in sensitivity.
- PDO drug responses showed good correlation with clinical outcomes in platinum-sensitive, resistant, and refractory patients.
Conclusions:
- In vitro drug sensitivity testing using ovarian cancer PDOs is feasible.
- PDOs accurately reflect patient responses to chemotherapy.
- This model supports the development of precision chemotherapy and drug screening.
